A citation-based method for searching scientific literature

Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin, Eric Winquist, Gloria E Sarto, Judy E Garber, Carol J Fabian, Pascal Pujol, Elizabeth Maunsell, Patricia Farmer, Karen A Gelmon, Dongsheng Tu, Harriet Richardson. N Engl J Med 2011
Times Cited: 557







List of co-cited articles
644 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
340
51

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
33

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Bernard Fisher, Joseph P Costantino, D Lawrence Wickerham, Reena S Cecchini, Walter M Cronin, Andre Robidoux, Therese B Bevers, Maureen T Kavanah, James N Atkins, Richard G Margolese,[...]. J Natl Cancer Inst 2005
832
30

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
230
27

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
388
24

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
Jack Cuzick, Ivana Sestak, Bernardo Bonanni, Joseph P Costantino, Steve Cummings, Andrea DeCensi, Mitch Dowsett, John F Forbes, Leslie Ford, Andrea Z LaCroix,[...]. Lancet 2013
269
19

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch Dowsett. J Natl Cancer Inst 2007
267
19

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. JAMA 2006
19

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.
S G Smith, I Sestak, A Forster, A Partridge, L Side, M S Wolf, R Horne, J Wardle, J Cuzick. Ann Oncol 2016
127
18

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Simon Cawthorn, Robert E Mansel, Sibylle Loibl, Bernardo Bonanni, D Gareth Evans, Anthony Howell. Lancet 2020
40
45

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F Col, Jack Cuzick, Nancy E Davidson, Andrea Decensi, Carol Fabian, Leslie Ford,[...]. J Clin Oncol 2013
201
15


Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
13


Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Chyke A Doubeni, John W Epling, Martha Kubik, C Seth Landefeld,[...]. JAMA 2019
47
27

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.
Kala Visvanathan, Carol J Fabian, Elissa Bantug, Abenaa M Brewster, Nancy E Davidson, Andrea DeCensi, Justin D Floyd, Judy E Garber, Erin W Hofstatter, Seema A Khan,[...]. J Clin Oncol 2019
47
27

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Umberto Veronesi, Patrick Maisonneuve, Nicole Rotmensz, Bernardo Bonanni, Peter Boyle, Giuseppe Viale, Alberto Costa, Virgilio Sacchini, Roberto Travaglini, Giuseppe D'Aiuto,[...]. J Natl Cancer Inst 2007
149
11

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
Andrea DeCensi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Silvia Caviglia, Franca Avino, Laura Cortesi, Cristiana Taverniti, Maria Grazia Pacquola, Fabio Falcini, Marcella Gulisano,[...]. J Clin Oncol 2019
57
19

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
665
10

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
J Cuzick, J Forbes, R Edwards, M Baum, S Cawthorn, A Coates, A Hamed, A Howell, T Powles. Lancet 2002
521
10


Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
867
10

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Andrew N Freedman, Binbing Yu, Mitchell H Gail, Joseph P Costantino, Barry I Graubard, Victor G Vogel, Garnet L Anderson, Worta McCaskill-Stevens. J Clin Oncol 2011
123
10

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
10

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.
L S Donnelly, D G Evans, J Wiseman, J Fox, R Greenhalgh, J Affen, I Juraskova, P Stavrinos, S Dawe, J Cuzick,[...]. Br J Cancer 2014
59
15

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Jack Cuzick, John F Forbes, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell. J Natl Cancer Inst 2007
357
9

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
S R Cummings, S Eckert, K A Krueger, D Grady, T J Powles, J A Cauley, L Norton, T Nickelsen, N H Bjarnason, M Morrow,[...]. JAMA 1999
9

Stratification of breast cancer risk in women with atypia: a Mayo cohort study.
Amy C Degnim, Daniel W Visscher, Hal K Berman, Marlene H Frost, Thomas A Sellers, Robert A Vierkant, Shaun D Maloney, V Shane Pankratz, Piet C de Groen, Wilma L Lingle,[...]. J Clin Oncol 2007
149
8

Atypical hyperplasia of the breast--risk assessment and management options.
Lynn C Hartmann, Amy C Degnim, Richard J Santen, William D Dupont, Karthik Ghosh. N Engl J Med 2015
151
8

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Sharon L Bober, Lizbeth A Hoke, Rosemary B Duda, Meredith M Regan, Nadine M Tung. J Clin Oncol 2004
107
8

Chemoprevention for Breast Cancer.
Sandhya Pruthi, Ruth E Heisey, Therese B Bevers. Ann Surg Oncol 2015
31
25


Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
J A Cauley, L Norton, M E Lippman, S Eckert, K A Krueger, D W Purdie, J Farrerons, A Karasik, D Mellstrom, K W Ng,[...]. Breast Cancer Res Treat 2001
473
8

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Erika A Waters, Timothy S McNeel, Worta McCaskill Stevens, Andrew N Freedman. Breast Cancer Res Treat 2012
104
7

Benign breast disease and the risk of breast cancer.
Lynn C Hartmann, Thomas A Sellers, Marlene H Frost, Wilma L Lingle, Amy C Degnim, Karthik Ghosh, Robert A Vierkant, Shaun D Maloney, V Shane Pankratz, David W Hillman,[...]. N Engl J Med 2005
500
7

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
7

Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
Erika A Waters, Kathleen A Cronin, Barry I Graubard, Paul K Han, Andrew N Freedman. Cancer Epidemiol Biomarkers Prev 2010
109
7


Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
493
7

Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Therese B Bevers, Mark Helvie, Ermelinda Bonaccio, Kristine E Calhoun, Mary B Daly, William B Farrar, Judy E Garber, Richard Gray, Caprice C Greenberg, Rachel Greenup,[...]. J Natl Compr Canc Netw 2018
123
7


The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions.
Suzanne B Coopey, Emanuele Mazzola, Julliette M Buckley, John Sharko, Ahmet K Belli, Elizabeth M H Kim, Fernanda Polubriaginof, Giovanni Parmigiani, Judy E Garber, Barbara L Smith,[...]. Breast Cancer Res Treat 2012
73
8



Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.
Kevin C Oeffinger, Elizabeth T H Fontham, Ruth Etzioni, Abbe Herzig, James S Michaelson, Ya-Chen Tina Shih, Louise C Walter, Timothy R Church, Christopher R Flowers, Samuel J LaMonte,[...]. JAMA 2015
740
6

Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Jack Cuzick, Jane Warwick, Elizabeth Pinney, Stephen W Duffy, Simon Cawthorn, Anthony Howell, John F Forbes, Ruth M L Warren. J Natl Cancer Inst 2011
270
6

Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.
Meghna S Trivedi, Austin M Coe, Alejandro Vanegas, Rita Kukafka, Katherine D Crew. Cancer Prev Res (Phila) 2017
21
28

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Elizabeth Barrett-Connor, Lori Mosca, Peter Collins, Mary Jane Geiger, Deborah Grady, Marcel Kornitzer, Michelle A McNabb, Nanette K Wenger. N Engl J Med 2006
668
6

Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model.
Jeffrey A Tice, Steven R Cummings, Rebecca Smith-Bindman, Laura Ichikawa, William E Barlow, Karla Kerlikowske. Ann Intern Med 2008
339
6

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Paul E Goss, James N Ingle, Kathleen I Pritchard, Nicholas J Robert, Hyman Muss, Julie Gralow, Karen Gelmon, Tim Whelan, Kathrin Strasser-Weippl, Sheldon Rubin,[...]. N Engl J Med 2016
313
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.